Supplementary Figure 2

(a) FGFR4

FGF1 (30 min) Merged

scr siFGFR4 #2

FGFR4

FGF1 (30 min) Merged

(b) pFGFR4

FGF1 (30 min) Merged

scr siFGFR4 #2

pFGFR4

FGF1 (30 min) Merged
Supplementary Figure 4

(a) MTS ∆A₄₉₀ (% control) - TAK632 (μM)

(b) MTS ∆A₄₉₀ (% control) - RO51267663 (μM)

(c) MTS ∆A₄₉₀ (% control) - U0126 (μM)

TAK632 (pan-RAF)

µM:
- 0.03
- 0.06
- 0.12
- 0.3
- 0.5
- 1

RO51267663 (RAF/MEK)

µM:
- 0.001
- 0.003
- 0.007
- 0.015
- 0.03
- 0.06
- 0.12
- 0.25
- 0.5
- 1
- 2

U0126 (MEK)

µM:
- 0.3
- 1.2
- 4.8
- 19.2
Supplementary Figure 5

a) Graph showing the effect of LY294002 (PI3K) on MTS ΔA_{490} (% control) with LY294002 (μM) on the x-axis.

b) Graph showing the effect of SHP099 (PTPN11) on MTS ΔA_{490} (% control) with SHP099 (μM) on the x-axis.

c) Graph showing the effect of SHP099 (PTPN11) on MTS ΔA_{490} (% control) with FGF1 and SHP099 (μM) on the x-axis.
Supplementary Figure 6

| NVP-AUY922 (nM) | RMS559 | RH30 |
|-----------------|--------|------|
|                 | 1000   | 1000 |
|                 | 500    | 500  |
|                 | 250    | 250  |
|                 | 125    | 125  |
|                 | 62.5   | 62.5 |
|                 | 31.25  | 31.25|
|                 | 15.625 | 15.625|
|                 | 7.8125 | 7.8125|
|                 | 3.90625| 3.90625|
|                 | 1.953125| 1.953125|
|                 | 0.9765625| 0.9765625|
|                 | 0.48828125| 0.48828125|

- pFGFR
- FGFR4
- pPLCγ
- PLCγ
- pERK
- γ-tubulin
Supplementary Figure 7

(a) Western blot analysis of pERK1/2 (37 kDa) and γ-tubulin (50 kDa) after treatment with different doses of LY2874455 (mg/kg) for 3 hours and 6 hours.

(b) Tumor volume (mm³) over time (days) for Vehicle and LY2874455 (6 mg/kg).

(c) Body weight (relative to day 1) over time (days) for Vehicle and LY2874455 (6 mg/kg).

(d) Body weight (relative to day 1) over time (days) for Vehicle and FGF401 (10 mg/kg).